Huaren Pharmaceutical(SZ:300110) 中国基金报·2025-08-27 01:58Core Viewpoint - The recent developments at Huaren Pharmaceutical, including the resignation of Chairman Zhang Li and his subsequent house arrest, raise concerns about the company's governance and financial health, especially following a significant financial loss in 2024 [2][3][15]. Group 1: Leadership Changes - Zhang Li has been placed under house arrest by the local police, which is unrelated to the company or its operations [2]. - Following this, Zhang Li submitted his resignation from all positions within the company, including Chairman and legal representative [3]. - The board of directors has appointed Hou Ruipeng to act as the interim Chairman and legal representative while the company initiates the process for a formal election [5]. Group 2: Financial Performance - Huaren Pharmaceutical reported a revenue of 1.353 billion yuan in 2024, a decrease of 17.3% year-on-year [15]. - The company experienced a net loss of 1.368 billion yuan, marking a staggering decline of 827.67% compared to the previous year [15]. - The significant losses were attributed to a full provision for credit impairment losses related to a debt of 1.3478 billion yuan owed to Guoyao Medicine [16]. Group 3: Historical Context - Zhang Li was appointed as Chairman on April 29, 2025, just months before his current legal troubles [6]. - The company has faced severe financial difficulties, erasing over a decade's worth of accumulated profits and resulting in a net loss exceeding 150 million yuan [15]. - The previous Chairman, Yang Xiaodong, also resigned shortly after the financial report was released, indicating potential instability in leadership [16].